Inventor · disambiguated record
Michael Mullan
Also filed as: MULLAN MICHAEL · MULLAN MICHAEL J · MULLAN MICHAEL JOHN
18 granted patents·29 pending applications·428 citations·filing 1992–2024
94Inventor score
Files withMULLAN MICHAEL J6ROSKAMP RES LLC6ALZHEIMER S INST OF AMERICA IN5UNIV SOUTH FLORIDA3ARCHER PHARMACEUTICALS INC2
Top patents by PatentIndex Score
47 records- 0196US5877015AAPP770 mutant in alzheimer's diseaseIMPERIAL COLLEGE·Filed 1992·Granted Mar 2, 1999·178 cites·12 claims
- 0293US5455169ANucleic acids for diagnosing and modeling Alzheimer's diseaseALZHEIMER S INST OF AMERICA IN·Filed 1992·Granted Oct 3, 1995·124 cites·12 claims
- 0391US7538258B2Transgenic mouse expressing an APP 670/671 mutationALZHEIMER S INST OF AMERICA IN·Filed 2007·Granted May 26, 2009·6 cites·6 claims
- 0487US5795963AAmyloid precursor protein in alzheimer's diseaseALZHEIMER S INST OF AMERICA·Filed 1997·Granted Aug 18, 1998·61 cites·1 claims
- 0578US6818448B2Isolated cell comprising HAPP 670/671 DNAS sequencesALZHEIMER S INST OF AMERICA IN·Filed 2001·Granted Nov 16, 2004·5 cites·6 claims
- 0677US2009203033A1Test and model for alzheimer's diseaseMULLAN MICHAEL JOHN·Filed 2009·Application pending·0 cites
- 0776US11865107B2Pharmaceutical compositionASCLEPIUS PHARMACEUTICAL LLC·Filed 2020·Granted Jan 9, 2024·1 cites·15 claims
- 0874US8067372B2Modulation of angiogenesis by A-beta peptide fragmentsPARIS DANIEL·Filed 2006·Granted Nov 29, 2011·3 cites·20 claims
- 0971US12485112B2Pharmaceutical compositionASCLEPIUS PHARMACEUTICAL LLC·Filed 2024·Granted Dec 2, 2025·0 cites·16 claims
- 1069US7589168B2Inhibition of angiogenesis by A-β peptidesROSKAMP RES LLC·Filed 2002·Granted Sep 15, 2009·6 cites·8 claims
- 1168US2010331280A1Modulation of the Phospholipase A2 Pathway as a TherapeuticPARIS DANIEL C·Filed 2009·Application pending·0 cites
- 1267US2005144658A1Test and model for Alzheimer's diseaseFiled 2004·Application pending·0 cites
- 1362US7052852B1CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's diseaseROSKAMP RES LLC·Filed 2003·Granted May 30, 2006·5 cites·5 claims
- 1460US2004048238A1Method and assay for diagnosing substance dependencyFiled 2003·Application pending·0 cites
- 1560US2003165958A1Test and model for Alzheimer's diseaseELAN PHARM INC·Filed 2003·Application pending·0 cites
- 1658US2010093810A1Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and MicrogliosisALZHEIMER S INST OF AMERICA IN·Filed 2009·Application pending·0 cites
- 1757US2010119599A1Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid productionARCHER PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 1855US6011019AVasoactive effects and free radical generation by β-amyloid peptidesUNIV SOUTH FLORIDA·Filed 1996·Granted Jan 4, 2000·16 cites·13 claims
- 1955US2008058330A1Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use ThereofROSKAMP RES LLC·Filed 2007·Application pending·0 cites
- 2054US2002006624A1Method and assay for diagnosing substance dependencyFiled 2001·Application pending·0 cites
- 2154US2007191409A1Compounds for inhibiting beta-amyloid production and methods of identifying the compoundsROSKAMP RES LLC·Filed 2006·Application pending·0 cites
- 2254US2007185130A1Compounds for inhibiting beta-amyloid production and methods of identifying the compoundsROSKAMP RES LLC·Filed 2006·Application pending·0 cites
- 2354US2006188938A1Compounds for inhibiting beta-amyloid production and methods of identifying the compoundsMULLAN MICHAEL J·Filed 2006·Application pending·0 cites
- 2453US8236346B2Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomerMULLAN MICHAEL J·Filed 2008·Granted Aug 7, 2012·0 cites·14 claims
- 2553US2007160615A1Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of Alzheimer's diseaseTAN JUN·Filed 2006·Application pending·0 cites
- 2651US7732467B2Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosisALZHEIMER S INST OF AMERICA IN·Filed 2004·Granted Jun 8, 2010·0 cites·12 claims
- 2751US2007037855A1Compounds for inhibiting beta-amyloid production and methods of identifying the compoundsMULLAN MICHAEL J·Filed 2006·Application pending·0 cites
- 2851US2010130416A1Modulation of angiogenesis by a-beta peptide fragmentsARCHER PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 2950US6300540B1Transgenic mouse expressing an APP-FAD DNA sequenceELAN PHARM INC·Filed 1995·Granted Oct 9, 2001·11 cites·6 claims
- 3050US2010216784A1Compounds for Inhibiting Beta-Amyloid Production and Methods of Identifying the CompoundsMULLAN MICHAEL J·Filed 2010·Application pending·0 cites
- 3150US2010215735A1Compounds for Inhibiting Beta-Amyloid Production and Methods of Identifying the CompoundsMULLAN MICHAEL J·Filed 2010·Application pending·0 cites
- 3249US2022081415A1Amino Acid Derivatives for the Treatment of Inflammatory DiseasesTHE ROSKAMP INST·Filed 2020·Application pending·0 cites
- 3348US2005089939A1Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathologyFiled 2004·Application pending·0 cites
- 3447US6140309AVasoactive effects and free radical generation by β-amyloid peptidesUNIV SOUTH FLORIDA·Filed 1996·Granted Oct 31, 2000·6 cites·9 claims
- 3544US2004229816A1Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitorsFiled 2004·Application pending·0 cites
- 3643US2016030407A1Method of Treating Inflammatory Lung DiseaseRCP DEV INC·Filed 2015·Application pending·0 cites
- 3743US2002137108A1CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's diseaseFiled 2001·Application pending·0 cites
- 3843US2009017112A1Compounds for Inhibiting Beta-Amyloid ProductionROSKAMP RES LLC·Filed 2007·Application pending·0 cites
- 3943US2004146949A1Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's diseaseTAN JUN·Filed 2003·Application pending·0 cites
- 4041US2003077573A1Methods of identifying compounds useful in the inhibition of neurodegenerative diseaseFiled 2002·Application pending·0 cites
- 4140US8236347B2Pharmaceutical compositions for reducing amyloid deposition, amyloid neurotoxicity, and microgliosisMULLAN MICHAEL J·Filed 2010·Granted Aug 7, 2012·0 cites·8 claims
- 4240US6787318B1Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathologyROSKAMP RES INST LLC·Filed 2000·Granted Sep 7, 2004·6 cites·12 claims
- 4340US2003077667A1Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's diseaseFiled 2002·Application pending·0 cites
- 4437US2002102259A1Methods and compositions for stimulating CD 45 and thereby suppressing microglial activation associated with Alzheimer's diseaseFiled 2001·Application pending·0 cites
- 4536US2002025527A1Methods and assays for diagnosing alzheimer's diseaseFiled 2001·Application pending·0 cites
- 4636US2004158883A1Organic anion transport polypeptide related protein-4 (OATPRP4) gene in Tourette syndrome and related disordersFiled 2003·Application pending·0 cites
- 4729US7605149B1Modulation of the phospholipase A2 pathway as a therapeuticUNIV SOUTH FLORIDA·Filed 1999·Granted Oct 20, 2009·0 cites·10 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →